Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • CH 223191: Precision AhR Antagonist for Toxicology & Stem Ce

    2026-05-26

    Applied Workflows with CH 223191: Dissecting AhR Pathways in Toxicology and Regenerative Biology

    Introduction: Pinpointing AhR Signaling with CH 223191

    Environmental toxicology and regenerative biology converge on a critical molecular switch: the aryl hydrocarbon receptor (AhR). This ligand-activated transcription factor mediates the biological effects of environmental contaminants such as dioxins, including TCDD, and orchestrates pathways central to stem cell fate and epithelial barrier integrity. CH 223191, a potent and selective aryl hydrocarbon receptor antagonist, is the tool of choice for researchers aiming to unravel these mechanisms with quantitative precision. By inhibiting AhR activity at nanomolar concentrations, CH 223191 enables not only the dissection of dioxin toxicity mechanisms but also the interrogation of microbiota-driven stem cell differentiation and mucosal repair processes in disease models such as ulcerative colitis.

    Experimental Setup: Principle, Preparation, and Core Advantages

    CH 223191 (CAS 301326-22-7) is a solid compound with a molecular weight of 333.39 and the chemical formula C19H19N5O. Its mechanism centers on antagonizing AhR-mediated transcriptional activation, effectively blocking downstream targets such as cytochrome P450 1A1 (CYP1A1). The compound’s high purity (>98% by HPLC and NMR) and validated storage conditions (stable at –20°C, but solutions should be used promptly) provide confidence in experimental reproducibility. Notably, CH 223191 is insoluble in water but demonstrates excellent solubility in DMSO (≥33.3 mg/mL) and ethanol (≥2.31 mg/mL), supporting diverse in vitro and in vivo applications. According to the product information, the compound exhibits an IC50 of ~30 nM in cell-based assays, underscoring its potency as an AhR signaling pathway inhibitor.

    Step-by-Step Workflow: Enhancing Experimental Design with CH 223191

    Integrating CH 223191 into your experimental pipeline can streamline toxicological and regenerative studies, from assay setup to endpoint quantification. Below is a synthesized workflow, drawing from both published protocols and recent advances in the field:

    • 1. Compound Preparation: Dissolve CH 223191 in DMSO to prepare a 10 mM stock solution. For cell-based assays, dilute into culture medium to achieve a working concentration between 100 nM and 3 μM, ensuring DMSO does not exceed 0.1% (v/v).
    • 2. Toxicant or Agonist Challenge: For dioxin toxicity studies, pre-treat cells or animals with CH 223191 30–60 minutes prior to TCDD (or other AhR ligand) exposure. In vivo, oral or intraperitoneal administration at 10–20 mg/kg is common, but always optimize dose and schedule based on model sensitivity and endpoint.
    • 3. Endpoint Analysis: Quantify AhR pathway activity via CYP1A1 mRNA (RT-qPCR), protein (Western blot), or enzymatic activity (EROD assay). Additional markers include IL-22 in regenerative models, and plasma ALT/AST for hepatic toxicity assessment.
    • 4. Stem Cell Differentiation Assays: In regenerative biology, monitor lineage commitment by measuring markers such as Lgr5 (ISC), MUC2, LYZ, and ChgA (differentiated lineages) by immunofluorescence or PCR, as demonstrated in the Li et al. study.

    Protocol Parameters

    • Working concentration for cell assays: 100 nM – 3 μM CH 223191 in culture medium; DMSO ≤ 0.1% (v/v).
    • In vivo dosing (rodent models): 10–20 mg/kg CH 223191 administered intraperitoneally or orally, 30–60 min before AhR agonist exposure.
    • Incubation time for transcriptional assays: 6–24 hours post-treatment before harvesting cells or tissues for endpoint analysis.

    Key Innovation from the Reference Study

    The reference study by Li et al. uncovers a pivotal axis linking microbiota-driven tryptophan metabolism, AhR activation, and intestinal stem cell (ISC) differentiation in ulcerative colitis repair. By using an AhR antagonist to block this pathway, the investigators demonstrated that the beneficial effects of Huangqin decoction (HQD) on mucosal healing are dependent on both microbiota-derived indole metabolites and AhR signaling. In practical terms, this finding enables researchers to design assays that parse the individual contributions of microbial metabolites and AhR activation by incorporating CH 223191 as a pathway-specific inhibitor. This approach is especially valuable in complex models where both host and microbial factors converge to drive epithelial regeneration or inflammation.

    Advanced Applications and Comparative Advantages

    CH 223191 stands out for its nanomolar potency and selectivity, enabling robust and reproducible inhibition of AhR signaling in both environmental toxicology and regenerative biology models. Compared to older, less selective inhibitors, CH 223191 minimizes off-target effects and confounding background noise, as detailed in recent comparative analyses. Its performance in modulating cytochrome P450 1A1 expression and mitigating TCDD-induced toxicity—such as suppression of plasma AST/ALT elevation and prevention of weight loss—has been quantitatively validated (see product documentation). Moreover, the compound’s compatibility with diverse in vitro, ex vivo, and in vivo platforms broadens its utility, from screening environmental pollutants to dissecting stem cell differentiation cues.

    For researchers seeking to bridge environmental toxicology and regenerative medicine, CH 223191 provides a molecular handle to differentiate between direct toxicant effects and downstream regenerative responses. Its use complements the mechanistic insights discussed in mechanistic reviews and extends validated workflows from dioxin toxicity to epithelial repair, as further detailed in applied protocol articles.

    Troubleshooting and Optimization Tips

    • Compound Solubility: Always prepare fresh DMSO stock solutions and avoid repeated freeze-thaw cycles. Due to water insolubility, ensure complete dissolution in DMSO before diluting into aqueous media; vortex and, if necessary, briefly sonicate stocks.
    • Vehicle Effects: Maintain DMSO concentrations below 0.1% in final cell cultures or animal dosing solutions to prevent cytotoxicity or altered pharmacokinetics.
    • Timing and Sequence: For pathway dissection, pre-treat with CH 223191 prior to AhR agonist or toxicant challenge to achieve maximal pathway inhibition. Delayed addition may result in incomplete pathway blockade.
    • Control Groups: Always include both vehicle-only and agonist-only controls, in addition to CH 223191–treated groups, to distinguish specific pathway effects from generic stress responses.
    • Endpoint Selection: Select endpoints sensitive to AhR modulation—CYP1A1 activity, IL-22 secretion, and specific stem cell lineage markers—to maximize assay responsiveness.

    Outlook: Implications and Next Steps

    The convergence of environmental toxicology and regenerative biology, exemplified by studies like Li et al., highlights the centrality of AhR signaling in both disease pathogenesis and tissue repair. As microbiota-derived metabolites and environmental toxins increasingly shape research priorities, CH 223191 will remain a cornerstone for mechanistic investigations. The precision and workflow compatibility of this aryl hydrocarbon receptor antagonist, supplied by APExBIO, facilitate reproducible experiments that can parse subtle differences in pathway activation and inhibition. Future work leveraging CH 223191 will refine our understanding of the microbiota–tryptophan–AhR–ISC differentiation axis and drive forward new interventions in both toxicology and regenerative medicine.